Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeu… Read more
Panacea Biotec Limited (PANACEABIO) - Net Assets
Latest net assets as of September 2025: ₹8.22 Billion INR
Based on the latest financial reports, Panacea Biotec Limited (PANACEABIO) has net assets worth ₹8.22 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹12.54 Billion) and total liabilities (₹4.32 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹8.22 Billion |
| % of Total Assets | 65.53% |
| Annual Growth Rate | 7.07% |
| 5-Year Change | N/A |
| 10-Year Change | 84.71% |
| Growth Volatility | 57.05 |
Panacea Biotec Limited - Net Assets Trend (2005–2025)
This chart illustrates how Panacea Biotec Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Panacea Biotec Limited (2005–2025)
The table below shows the annual net assets of Panacea Biotec Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹8.31 Billion | -0.91% |
| 2024-03-31 | ₹8.38 Billion | -0.22% |
| 2023-03-31 | ₹8.40 Billion | -3.84% |
| 2022-03-31 | ₹8.74 Billion | +477.07% |
| 2021-03-31 | ₹-2.32 Billion | -218.36% |
| 2020-03-31 | ₹1.96 Billion | -43.65% |
| 2019-03-31 | ₹3.47 Billion | +13.63% |
| 2018-03-31 | ₹3.06 Billion | -16.52% |
| 2017-03-31 | ₹3.66 Billion | -18.56% |
| 2016-03-31 | ₹4.50 Billion | -5.27% |
| 2015-03-31 | ₹4.75 Billion | -8.39% |
| 2014-03-31 | ₹5.18 Billion | -18.14% |
| 2013-03-31 | ₹6.33 Billion | -28.20% |
| 2012-03-31 | ₹8.82 Billion | +34.56% |
| 2011-03-31 | ₹6.55 Billion | -7.13% |
| 2010-03-31 | ₹7.06 Billion | +13.87% |
| 2009-03-31 | ₹6.20 Billion | -10.98% |
| 2008-03-31 | ₹6.96 Billion | +55.60% |
| 2007-03-31 | ₹4.47 Billion | +82.09% |
| 2006-03-31 | ₹2.46 Billion | +15.88% |
| 2005-03-31 | ₹2.12 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Panacea Biotec Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4454.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹7.80 Billion | 93.43% |
| Common Stock | ₹61.30 Million | 0.73% |
| Other Comprehensive Income | ₹-431.92 Million | -5.17% |
| Other Components | ₹919.39 Million | 11.01% |
| Total Equity | ₹8.35 Billion | 100.00% |
Panacea Biotec Limited Competitors by Market Cap
The table below lists competitors of Panacea Biotec Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
REITMANS CDA LTD
F:CX40
|
$56.50 Million |
|
3D Global Biotech Inc.
TWO:6808
|
$56.51 Million |
|
Centro de Imagem Diagnósticos S.A
SA:AALR3
|
$56.52 Million |
|
Orthex Oyj
HE:ORTHEX
|
$56.52 Million |
|
Udaipur Cement Works Limited
NSE:UDAICEMENT
|
$56.45 Million |
|
Panda Financial Holding Corp Ltd
SHG:600599
|
$56.44 Million |
|
OCK Group Bhd
KLSE:0172
|
$56.44 Million |
|
Galaxy Gaming Inc
OTCQB:GLXZ
|
$56.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Panacea Biotec Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,420,460,000 to 8,347,900,000, a change of -72,560,000 (-0.9%).
- Net loss of 83,700,000 reduced equity.
- Other comprehensive income decreased equity by 8,791,119,999.
- Other factors increased equity by 8,802,259,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-83.70 Million | -1.0% |
| Other Comprehensive Income | ₹-8.79 Billion | -105.31% |
| Other Changes | ₹8.80 Billion | +105.44% |
| Total Change | ₹- | -0.86% |
Book Value vs Market Value Analysis
This analysis compares Panacea Biotec Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.54x to 2.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹37.15 | ₹317.20 | x |
| 2006-03-31 | ₹41.44 | ₹317.20 | x |
| 2007-03-31 | ₹80.63 | ₹317.20 | x |
| 2008-03-31 | ₹98.52 | ₹317.20 | x |
| 2009-03-31 | ₹86.58 | ₹317.20 | x |
| 2010-03-31 | ₹98.25 | ₹317.20 | x |
| 2011-03-31 | ₹102.60 | ₹317.20 | x |
| 2012-03-31 | ₹142.87 | ₹317.20 | x |
| 2013-03-31 | ₹102.15 | ₹317.20 | x |
| 2014-03-31 | ₹83.71 | ₹317.20 | x |
| 2015-03-31 | ₹76.94 | ₹317.20 | x |
| 2016-03-31 | ₹73.24 | ₹317.20 | x |
| 2017-03-31 | ₹58.07 | ₹317.20 | x |
| 2018-03-31 | ₹50.40 | ₹317.20 | x |
| 2019-03-31 | ₹57.21 | ₹317.20 | x |
| 2020-03-31 | ₹32.45 | ₹317.20 | x |
| 2021-03-31 | ₹-37.34 | ₹317.20 | x |
| 2022-03-31 | ₹143.12 | ₹317.20 | x |
| 2023-03-31 | ₹137.73 | ₹317.20 | x |
| 2024-03-31 | ₹137.48 | ₹317.20 | x |
| 2025-03-31 | ₹136.64 | ₹317.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Panacea Biotec Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.50%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.54x
- Recent ROE (-1.00%) is below the historical average (-0.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 12.87% | 8.32% | 0.70x | 2.22x | ₹60.90 Million |
| 2006 | 24.11% | 10.93% | 0.54x | 4.11x | ₹346.78 Million |
| 2007 | 27.53% | 17.53% | 0.89x | 1.76x | ₹940.23 Million |
| 2008 | 18.53% | 15.33% | 0.65x | 1.87x | ₹593.71 Million |
| 2009 | -10.70% | -8.37% | 0.46x | 2.78x | ₹-1.28 Billion |
| 2010 | 10.33% | 8.04% | 0.53x | 2.41x | ₹23.47 Million |
| 2011 | 22.29% | 12.39% | 0.67x | 2.68x | ₹797.74 Million |
| 2012 | -23.50% | -28.96% | 0.35x | 2.29x | ₹-2.93 Billion |
| 2013 | -37.44% | -38.50% | 0.33x | 2.94x | ₹-2.97 Billion |
| 2014 | -21.87% | -21.99% | 0.26x | 3.79x | ₹-1.63 Billion |
| 2015 | -22.60% | -15.50% | 0.36x | 4.10x | ₹-1.54 Billion |
| 2016 | -4.08% | -2.80% | 0.35x | 4.13x | ₹-631.51 Million |
| 2017 | -15.80% | -10.70% | 0.29x | 5.06x | ₹-917.67 Million |
| 2018 | -23.97% | -12.62% | 0.36x | 5.21x | ₹-1.05 Billion |
| 2019 | 10.77% | 8.34% | 0.33x | 3.93x | ₹26.87 Million |
| 2020 | -97.73% | -36.16% | 0.39x | 6.99x | ₹-2.14 Billion |
| 2021 | 0.00% | -23.91% | 0.52x | 0.00x | ₹-1.25 Billion |
| 2022 | 123.01% | 163.57% | 0.37x | 2.01x | ₹9.91 Billion |
| 2023 | -3.94% | -7.27% | 0.36x | 1.51x | ₹-1.18 Billion |
| 2024 | -0.14% | -0.21% | 0.44x | 1.47x | ₹-853.78 Million |
| 2025 | -1.00% | -1.50% | 0.43x | 1.54x | ₹-918.49 Million |
Industry Comparison
This section compares Panacea Biotec Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $16,110,731,100
- Average return on equity (ROE) among peers: 4.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Panacea Biotec Limited (PANACEABIO) | ₹8.22 Billion | 12.87% | 0.53x | $56.46 Million |
| Anthem Biosciences Ltd (ANTHEM) | $17.41 Billion | 22.13% | 0.16x | $17.29 Million |
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | $15.55 Million | -49.65% | 0.08x | $10.46 Million |
| Biocon Limited (BIOCON) | $14.77 Billion | 31.41% | 0.41x | $2.54 Billion |
| Blue Jet Healthcare Limited (BLUEJET) | $8.45 Billion | 19.37% | 0.25x | $134.93 Million |
| Concord Biotech Limited (CONCORDBIO) | $18.13 Billion | 20.50% | 0.12x | $346.78 Million |
| Dishman Carbogen Amcis Limited (DCAL) | $9.29 Billion | 6.11% | 1.42x | $103.76 Million |
| Haleos Labs Limited (HALEOSLABS) | $1.06 Billion | 16.78% | 1.56x | $129.20K |
| Lyka Labs Limited (LYKALABS) | $582.36 Million | -29.66% | 3.04x | $8.51 Million |
| ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) | $75.29 Billion | 0.00% | 0.00x | $1.21 Billion |